EP0090798A1 - Arzneimittel auf der basis eines antagonisten der p-substanz - Google Patents
Arzneimittel auf der basis eines antagonisten der p-substanzInfo
- Publication number
- EP0090798A1 EP0090798A1 EP81902811A EP81902811A EP0090798A1 EP 0090798 A1 EP0090798 A1 EP 0090798A1 EP 81902811 A EP81902811 A EP 81902811A EP 81902811 A EP81902811 A EP 81902811A EP 0090798 A1 EP0090798 A1 EP 0090798A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- substance
- trp
- pro
- prophylactically
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000003890 substance P antagonist Substances 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 229940079593 drug Drugs 0.000 title claims abstract description 14
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 claims abstract description 35
- 101800003906 Substance P Proteins 0.000 claims abstract description 35
- 206010061218 Inflammation Diseases 0.000 claims abstract description 16
- 230000004054 inflammatory process Effects 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 11
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 230000000069 prophylactic effect Effects 0.000 claims abstract description 9
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 9
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 claims abstract description 7
- 102100024304 Protachykinin-1 Human genes 0.000 claims abstract 12
- 239000013543 active substance Substances 0.000 claims abstract 3
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 claims description 19
- 230000000699 topical effect Effects 0.000 claims description 7
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000005557 antagonist Substances 0.000 abstract description 9
- 230000001960 triggered effect Effects 0.000 abstract 2
- 102400000096 Substance P Human genes 0.000 description 23
- 239000000126 substance Substances 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-Phenylalanine Chemical group OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000005036 nerve Anatomy 0.000 description 6
- 239000012530 fluid Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000001179 pupillary effect Effects 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 210000000554 iris Anatomy 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000001800 adrenalinergic effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- -1 t-butyloxycarbonyl Chemical group 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- OIXLLKLZKCBCPS-RZVRUWJTSA-N (2s)-2-azanyl-5-[bis(azanyl)methylideneamino]pentanoic acid Chemical compound OC(=O)[C@@H](N)CCCNC(N)=N.OC(=O)[C@@H](N)CCCNC(N)=N OIXLLKLZKCBCPS-RZVRUWJTSA-N 0.000 description 1
- WBIIPXYJAMICNU-AWEZNQCLSA-N (2s)-5-[amino-[(4-methylphenyl)sulfonylamino]methylidene]azaniumyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoate Chemical compound CC1=CC=C(S(=O)(=O)NC(N)=NCCC[C@H](NC(=O)OC(C)(C)C)C(O)=O)C=C1 WBIIPXYJAMICNU-AWEZNQCLSA-N 0.000 description 1
- HJMMCTZLXOVMFB-LBPRGKRZSA-N (4-nitrophenyl) (2s)-5-amino-2-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxopentanoate Chemical compound CC(C)(C)OC(=O)N[C@@H](CCC(N)=O)C(=O)OC1=CC=C([N+]([O-])=O)C=C1 HJMMCTZLXOVMFB-LBPRGKRZSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- 229930182820 D-proline Natural products 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010027646 Miosis Diseases 0.000 description 1
- MDXGYYOJGPFFJL-QMMMGPOBSA-N N(alpha)-t-butoxycarbonyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)OC(C)(C)C MDXGYYOJGPFFJL-QMMMGPOBSA-N 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- UEKYKRQIAQHOOZ-KBPBESRZSA-N Pro-Trp Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)[O-])C(=O)[C@@H]1CCC[NH2+]1 UEKYKRQIAQHOOZ-KBPBESRZSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000775 effect on neurotransmitter Effects 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 101150006061 neur gene Proteins 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 125000006501 nitrophenyl group Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Definitions
- the present invention relates to a Substance P antagonist for use in drugs for the prophylactic or therapeutic treatment of diseases released by Substance P, to a method of prophylactically or therapeutically treat ing such a disease, and to a drug for prophylactically. or therapeutically treating inflammations. More specifically, the invention relates to a Substance P antagonist which, in relation to Substance P, has a structure in which L-proline in position 2 has been replaced by D-proline, and L-phenylalanine in position 7 and
- the Substance P antagonist according to this inven tion thus is (D-Pro 2 , D-Trp 7 ' 9 ) Substance P having the formula
- transmitter substances or transmitters consist not only of substances related to adrenaline and acetyl choline (adrenergic and cholinergic nerves, respectively), but also of chemical compounds made up of a series of amino acids joined by peptide bonds, i.e. polypeptides or oligopeptides. In most cases, peptides alone can serve as such neur ⁇ transmitters. A whole series of peptides having this function are already known (see for example the papers published in the New England Journal of Medicine, Vol. 304, pp. 876-885 and 944-951).
- Substance P may be classed among transmitter substances because it has been shown to occur both in nerves transmitting impulses from peripheral parts of the body to the brain (afferents) and nerves extending from the brain (or peripheral ganglia) to different peripheral organs (efferents).
- Substance P is deemed to play an important part in the transmission of pain stimuli from the periphery to the brain.
- the efferent nerves which contain Substance P are apparently capable of stimulating secretion from endocrine glands and causing vasodilation and. contraction of smooth muscle.
- Substance P as synthetized by us has an inhibiting effect on inflammatory conditions in the body, especially the skin, the upper airpassages, the intestine and the eye.
- the present invention therefore relates to the Substance P antagonist (D-Pro 2 , D-Trp 7,9 ) Substance P for use in drugs for the prophylactic or therapeutic treatment of diseases released by substance P.
- the invention concerns a drug for the prophylactic or therapeutic treatment of inflammations, in particular inflammations in the eye.
- the invention relates to a method of prophylatically or therapeutically treating diseases released by Substance P, in particular such diseases as inflammations in the skin, the upper air-passages, the intestine and/or the eye.
- a suitable form for administration of the drug according to this invention is by topical application. Preparation of the Substance P antagonist according to the invention
- L-Arg-D-Pro-L-Lys-L-Pro-L-Gln-L-Gln-D-Trp-L-Phe-D-Trp-L-Leu-L-Met-NH 2 is prepared in a manner that is conventional in this particular field, viz. by the solid phase method described by R.B. Merrifield (J. Am. Chem. Soc., 85, (1963), 2149-2154).
- the solid phase employed is the benzhydrylamine resin described by Monahan et al. (Biochem. Biophys. Res. Com. 48, 1100-1105, (1972)).
- the starting materials employed in the preparation were Boc-Arg-Tos, Boc-Gln-ONp and Boc-Leu from Ferring AB, Malmö, Sweden; D-Pro, Pro, D-Trp and Phe from Merck Darmstadt, Federal Republic of Germany; and the benzhydrylamine resin from Beckman Inc.
- the synthesis was conducted by stages, starting from 5 g BHA resin, 0.51 meq. NH 2 /g, and the amino acids in the compound according to the invention were coupled according to the following schedule
- the peptide content of the material was 86.7%, based on the triacetate.
- the Substance P antagonist used for the present invention was shown to inhibit or cure inflammation by the following experiment.
- a similar inflammatory reaction can be evoked by infrared radiation of a restricted area on the iris.
- the Substance P antagonist according to this invention 90 nmol of the Substance P antagonist according to this invention were injected into the corpus vitrium of the left eye (3 rabbits).
- the right eye was used for control purposes and was given 0.9% saline.
- the irises of both eyes were exposed to infrared radiation.
- the amount of protein in the chamber fluid was measured, and it was found that the so-called light path in the left, treated eye was substantially unchanged, whereas it had been trebled in the right control eye.
- the experiments carried out to induce inflammation by infrared radiation also comprised experiments which showed that the minimum amount of recordable effects was 0.9 nmol of the Substance P antagonist in saline, while the minimum dose for maximum effect was 90 nmol in saline.
- the effect of the antagonist was found to be dose-dependent and rather linear.
- the Substance P antagonist according to the invention was used dissolved in saline for injection and eye drops, but other forms of administration for topical application by spraying, inhalation, instillation, insufflation and injection are also possible. Furthermore, salves, creams, suppositories, tablets, capsules and granulates can be prepared in which the active constituent consists of the Substance P antagonist according to this invention and the remaining ingredients are conventional inert carriers, diluents, excipients etc.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/SE1981/000292 WO1983001252A1 (en) | 1981-10-09 | 1981-10-09 | A drug based on a substance p antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP0090798A1 true EP0090798A1 (de) | 1983-10-12 |
Family
ID=20342922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP81902811A Ceased EP0090798A1 (de) | 1981-10-09 | 1981-10-09 | Arzneimittel auf der basis eines antagonisten der p-substanz |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0090798A1 (de) |
| JP (1) | JPS58501675A (de) |
| BE (1) | BE894602A (de) |
| IT (1) | IT1191028B (de) |
| WO (1) | WO1983001252A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3851152T2 (de) * | 1987-09-03 | 1995-01-26 | Univ Georgia Res Found | Cyclosporin-augenmittel. |
| FR2719476B1 (fr) * | 1994-05-05 | 1997-05-23 | Oreal | Utilisation d'un antagoniste de substance P dans une composition cosmétique et composition obtenue. |
| US6203803B1 (en) | 1994-12-14 | 2001-03-20 | Societe L'oreal S.A. | Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained |
| FR2719474B1 (fr) * | 1994-05-05 | 1996-05-31 | Oreal | Utilisation d'un antagoniste de substance P dans une composition cosmétique et composition obtenue. |
| FR2728265A1 (fr) * | 1994-12-19 | 1996-06-21 | Oreal | Utilisation d'un antagoniste de substance p dans une composition pharmaceutique |
| FR2732598B1 (fr) | 1995-04-10 | 1997-05-09 | Oreal | Utilisation de sel de metaux alcalino-terreux pour le traitement des prurits et des dysesthesies oculaires ou palpebraux |
| EP0737471A3 (de) * | 1995-04-10 | 2000-12-06 | L'oreal | Verwendung von Erdalkalimetallsalze als TNF-alpha Inhibitor in einer topischen Zusammensetzung und die so hergestellte Zusammensetzung |
| FR2737408B1 (fr) * | 1995-07-31 | 1997-09-05 | Oreal | Utilisation d'un antagoniste de bradykinine dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue |
| FR2738741B1 (fr) * | 1995-09-19 | 1997-12-05 | Oreal | Composition pour la teinture des fibres keratiniques, contenant un antagoniste de substance p |
| FR2740341B1 (fr) * | 1995-10-26 | 1997-12-19 | Oreal | Utilisation de sel de lanthanide, d'etain, de zinc, de manganese, d'yttrium, de cobalt, de baryum, de strontium dans une composition pour la peau |
| FR2740335B1 (fr) * | 1995-10-26 | 1997-12-19 | Oreal | Utilisation de sel de lanthanide, de lithium, d'etain, de zinc, de manganese ou d'yttrium comme antagoniste de substance p |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3954640A (en) * | 1973-06-27 | 1976-05-04 | Xerox Corporation | Electrostatic printing inks |
| US4052325A (en) * | 1974-12-23 | 1977-10-04 | Eastman Kodak Company | Liquid electrographic developer composition containing redispersible polyester toner and process |
| JPS5425833A (en) * | 1977-07-29 | 1979-02-27 | Canon Inc | Electrophotography |
| US4202785A (en) * | 1978-05-15 | 1980-05-13 | Eastman Kodak Company | Polyesterionomers having utility in liquid electrographic developer compositions |
| JPS5725832A (en) * | 1980-07-23 | 1982-02-10 | Olympus Optical Co | Light source apparatus for endoscope |
-
1981
- 1981-10-09 JP JP50331281A patent/JPS58501675A/ja active Pending
- 1981-10-09 EP EP81902811A patent/EP0090798A1/de not_active Ceased
- 1981-10-09 WO PCT/SE1981/000292 patent/WO1983001252A1/en not_active Application Discontinuation
-
1982
- 1982-10-05 BE BE0/209172A patent/BE894602A/fr not_active IP Right Cessation
- 1982-10-08 IT IT23678/82A patent/IT1191028B/it active
Non-Patent Citations (1)
| Title |
|---|
| See references of WO8301252A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| IT8223678A0 (it) | 1982-10-08 |
| WO1983001252A1 (en) | 1983-04-14 |
| BE894602A (fr) | 1983-01-31 |
| IT1191028B (it) | 1988-02-24 |
| JPS58501675A (ja) | 1983-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0275748B1 (de) | Peptid-Derivate und deren Verwendung in der Therapie | |
| US5902790A (en) | Pharmaceutical angiostatic dipeptide compositions and method of use thereof | |
| US6235716B1 (en) | Multivalent ligands which modulate angiogenesis | |
| RU2060998C1 (ru) | Способ получения пептидов, пептиды, иммуномодулирующая композиция и способ регуляции недостаточной или избыточной функции т-клеток у пациента | |
| CA2153789C (en) | Biologically active tgf-.beta.1 and tgf-.beta.2 peptides | |
| EP2552470B1 (de) | Peptide zur angiogeneseförderung und verwendung davon | |
| EP0298820A1 (de) | Peptid-Derivate und deren therapeutische Verwendung | |
| AU657723B2 (en) | Nonapeptide bombesin antagonists | |
| EP0090798A1 (de) | Arzneimittel auf der basis eines antagonisten der p-substanz | |
| EP0546068A1 (de) | Bioaktives egf-peptid welches für geweberegeneration und krebstherapie verwendbar ist | |
| EP1309613B1 (de) | Arzneimittel enthaltend analgetische peptide | |
| US5411943A (en) | Hepatoma treatment with somatostatin analogs | |
| NZ219764A (en) | Heterocyclic compounds and pharmaceutical compositions | |
| JPH04305535A (ja) | 細胞増殖抑制作用または細胞毒作用を有する治療用活性物質の組合せ | |
| AU2017261638A1 (en) | Aromatic-cationic peptides and uses of same | |
| WO1995003067A1 (en) | Pharmaceutical with immunomodulating activity | |
| EP0588873B1 (de) | Behandlung von leberkrebs | |
| WO2011119008A2 (en) | Peptides for promoting angiogenesis and an use thereof | |
| EP2198878A1 (de) | Polypeptide Bombesinantagonisten | |
| LV10109B (en) | New oligopeptides selectively inhibiting haemopoietic stem cells, pharmaceutical composition on their base and method for preparing thereof | |
| WO2006128293A1 (en) | Kinin b1 receptor peptide agonists and uses thereof | |
| JPS59130259A (ja) | 新規なペプチド誘導体、それらの製造方法およびそれらの薬学的使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19830526 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT CH DE FR GB LI NL SE |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
| 18R | Application refused |
Effective date: 19851102 |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: HAKANSON, ROLF Inventor name: HOERIG, JOACHIM |